![]() |
市场调查报告书
商品编码
1941880
内视镜黏膜下剥离术 (ESD) 市场规模、份额和趋势分析报告:按产品、适应症、最终用途、地区和细分市场预测 (2026-2033)Endoscopic Submucosal Dissection Market Size, Share & Trends Analysis Report By Product (Gastroscopes And Colonoscopes), By Indication (Stomach Cancer), By End Use (Hospitals), By Region, And Segment Forecasts, 2026 - 2033 |
||||||
全球内视镜黏膜下剥离术 (ESD) 市场预计到 2025 年将达到 3.915 亿美元,预计到 2033 年将达到 5.9758 亿美元。
预计2026年至2033年的复合年增长率为5.40%。消化器官系统癌症及其他相关疾病的日益普遍,以及内视镜技术和仪器的进步,正在推动对ESD等诊断和治疗程序的需求。
例如,根据美国癌症协会的估计,预计到2026年1月,全球将新增31510例胃癌病例,其中女性13610例,男性17900例。随着食道癌、胃癌和大肠直肠癌的发生率在全球范围内持续上升,对内视镜黏膜下剥离术(ESD)等先进治疗方法的需求也日益增长。
内视镜黏膜下剥离术 (ESD) 市场涵盖了主要用于整块切除胃肠道(GI)浅层肿瘤性病变的先进内视镜手术,特别适用于食道、胃和大肠。与通常适用于小型病灶的内视镜黏膜下剥离术 (EMR) 不同,ESD 可透过精确剥离黏膜下层,完整切除较大且更复杂的病灶。此手术使用 ESD 刀、黏膜下注射液、止血器械和高解析度内视镜等专用器械。 ESD 在早期胃肠道癌症的治疗中发挥着至关重要的作用,可实现更高的根治性切除率、更佳的病理评估以及器官功能的保留。
随着世界人口老化,内视镜黏膜下剥离术(ESD)的需求日益增长。人口老化预计会导致包括癌症在内的老龄化相关消化系统疾病发生率上升。根据美国癌症协会(2026年1月报告),胃癌主要影响老年人,平均确诊年龄为68岁,每年确诊患者中约有60%为65岁以上。许多老年患者也伴随其他健康问题,使得传统手术风险更高,也进一步加剧了ESD手术的需求。
内视镜黏膜下剥离术 (ESD) 市场的成长主要受胃肠道癌症 (GI 癌症) 负担加重的推动。主要的胃肠道癌症包括大肠直肠癌、胃癌、食道癌和胰腺癌。长期胃食道逆流症 (GERD)、遗传性疾病、胃部感染疾病、慢性胃炎、息肉的存在等因素均会增加胃癌的风险。根据美国癌症协会 (ACS) 预测,到 2024 年,美国将新增 152,810 例大肠直肠癌病例,其中结肠癌 106,590 例,直肠癌 46,220 例。大肠直肠癌也是全国第二大癌症相关死亡原因,预计到 2024 年将有 53,010 人死于此病。胃肠道癌症患者的这种成长趋势显着推动了对先进的微创治疗方法(如内视镜黏膜下剥离术 (ESD))的需求,这些治疗可提供更高的根治性切除率和更好的患者预后。
医疗专业人员对内视镜黏膜下剥离术(ESD)技术的认知度不断提高,培训计画的拓展也促进了市场成长。胃肠病学家和外科医生ESD技术水平的提升,扩大了这项先进手术的应用范围和可行性,尤其是在以往此类治疗资源有限的地区。众多医疗机构提供专业的培训和认证项目,这对掌握ESD知识和技能至关重要。例如,富士胶片医疗欧洲有限公司于2024年4月推出了“EndoGel”,这是一款用于掌握内视镜肌切开术(POEM)和内视镜黏膜下剥离术(ESD)技术的创新培训模型。该模拟器有两个版本:“EndoGel for ESD/POEM”和“EndoGel for ESD”,旨在为内视镜专家和医疗机构提供经济高效的培训。透过逼真的模拟训练,EndoGel旨在提高操作者的熟练度和患者的治疗效果。
人工智慧 (AI) 预计将在未来的内视镜黏膜下剥离术 (ESD) 市场中发挥日益重要的作用,其关键在于提高病灶检测、定性和治疗计划的准确性。 AI 驱动的影像分析和即时决策支援系统能够帮助内视镜医师准确识别病灶边界、评估浸润深度并优化切除策略。此外,将 AI 整合到机器人和内视镜平台中,可提高手术的准确性、一致性和疗效,同时也有助于培训并降低对操作者的依赖性。随着 AI 驱动的内视镜技术的不断成熟,预计临床效率将得到提升,治疗结果的差异性将降低,先进的 ESD 手术也将得到更广泛的应用。
The global endoscopic submucosal dissection market size was estimated at USD 391.50 million in 2025 and is projected to reach USD 597.58 million by 2033, growing at a CAGR of 5.40% from 2026 to 2033. The increasing prevalence of gastrointestinal cancers and other related disorders, and advancements in endoscopic technology & instrumentation, drive the demand for diagnostic and therapeutic procedures such as ESD.
For instance, the American Cancer Society estimates that in January 2026, there will be 31,510 new cases of stomach cancer, with 13,610 cases in women and 17,900 cases in men. As esophageal, gastric, and colorectal cancer rates continue to rise globally, the need for advanced procedures, such as ESD, is increasing.
The endoscopic submucosal dissection (ESD) market encompasses an advanced endoscopic procedure used mainly for en bloc removal of superficial neoplastic lesions within the gastrointestinal (GI) tract, particularly in the esophagus, stomach, and colon. In contrast to endoscopic mucosal resection (EMR), which is generally suited for smaller lesions, ESD allows for the complete resection of larger and more complex lesions through precise dissection of the submucosal layer. The procedure relies on specialized tools, including ESD knives, submucosal injection solutions, hemostatic devices, and high-definition endoscopes. ESD plays a critical role in the management of early-stage GI cancers, offering higher curative resection rates, improved pathological evaluation, and preservation of organ integrity.
The aging population worldwide is boosting the demand for ESD. As the global population ages, age-related gastrointestinal conditions, including cancers, are expected to rise. According to the American Cancer Society in January 2026, gastric cancer predominantly affects older individuals, with an average age of 68 when diagnosed, and 6 out of 10 diagnosed annually are 65 or older. Many older patients also have other health conditions, which make traditional surgery riskier, further contributing to the rising demand for ESD procedures.
The growth of the endoscopic submucosal dissection (ESD) market is driven by the rising burden of gastrointestinal (GI) cancers. Key GI cancer types include colorectal, gastric, esophageal, and pancreatic cancers. Factors such as long-standing gastroesophageal reflux disease (GERD), hereditary conditions, gastric infections, chronic gastritis, and the presence of polyps increase the risk of stomach cancer. According to the American Cancer Society (ACS), 152,810 new colorectal cancer cases are expected in the U.S. in 2024, including 106,590 colon cancer cases and 46,220 rectal cancer cases. Colorectal cancer also remains the second leading cause of cancer-related deaths in the country, with an estimated 53,010 deaths projected in 2024. This growing prevalence of GI cancers is significantly driving the demand for advanced, minimally invasive treatments such as ESD, which offer higher curative resection rates and better patient outcomes.
The growing awareness and training programs for healthcare professionals in ESD techniques contribute to market growth. The proficiency of gastroenterologists and surgeons in ESD has been increasing, enhancing both the reach and feasibility of this advanced procedure, particularly in areas that previously had limited access to such treatments. Various medical organizations offer specialized training and certification programs, which are important in gaining knowledge and expertise in ESD. For instance, in April 2024, FUJIFILM Healthcare Europe GmbH introduced EndoGel, an innovative training model designed for performing Peroral Endoscopic Myotomy (POEM) and Endoscopic Submucosal Dissection (ESD) procedures. This simulator is available in two versions such as EndoGel for ESD/POEM and EndoGel for ESD. It is designed to be cost effective for endoscopy professionals and healthcare institutions, aiming to enhance proficiency and patient outcomes through realistic simulation training.
Artificial intelligence (AI) is expected to play an increasingly important role in the future of the ESD market by enhancing lesion detection, characterization, and procedural planning. AI-powered image analysis and real-time decision-support systems can assist endoscopists in accurately identifying lesion margins, assessing invasion depth, and optimizing resection strategies. Furthermore, AI integration with robotic and endoscopic platforms can improve procedural precision, consistency, and outcomes, while supporting training and reducing operator dependency. As AI-enabled endoscopy continues to mature, it is likely to improve clinical efficiency, reduce variability in outcomes, and further expand the adoption of advanced ESD procedures.
Global Endoscopic Submucosal Dissection Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the endoscopic submucosal dissection market on the basis of product, indication, end use, and regions.